Respiratory Tract Diseases Clinical Trial
Official title:
Multicenter Open-label, Randomized Clinical Trial to Assess the Safety and Efficacy of Echinaforce® Junior Tablets in Two Dosages for the Therapy of Common Cold Symptoms in Children (4-12 Years)
NCT number | NCT02198391 |
Other study ID # | 920158 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 15, 2014 |
Est. completion date | August 7, 2015 |
Verified date | May 2021 |
Source | Bioforce AG |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to investigate safety and efficacy of Echinaforce Junior tablets in two dosages of 3 x 1 and 5 x 1 tablets per day in children 4 - 12 years old with acute colds.
Status | Completed |
Enrollment | 79 |
Est. completion date | August 7, 2015 |
Est. primary completion date | August 7, 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 4 Years to 12 Years |
Eligibility | Inclusion Criteria: - age between 4 and 12 years - signed informed consent by parents and optionally be the child - daily access to computer / internet - competence of german language Exclusion Criteria: - 13 years or older, younger than 4 years. - presence of sinusitis, otitis media, pneumonia, bronchitis (complicated cold) at inclusion - participation in a clinical study in the past 30 days - intake of antimicrobial, antiviral, immunesuppressive substances, salicyl-containing medicines or bronchovaxom at first treatment period - surgical intervention in the 3 months before inclusion or planned intervention during the observation period - Known diabetes mellitus - Known and treated allergic rhinitis, atopy or asthma - cystic fibrosis, bronchopulmonic dysplasia, COPD - immune system disorders, degenerative diseases (e.g. autoimmune disease like AIDS or leukosis) - metabolic or resorptive disorders - liver or kidney diseases - serious health problems - predisposition for complicated cold episodes in the judgement of the physician (sinusitis, otitis media, bronchitis, pneumonia) - known allergy to plants of the compositae family (camomile or dandelion) or any of the substances of the investigational product |
Country | Name | City | State |
---|---|---|---|
Switzerland | Dr. med. Arnold Bächler Facharzt FMH für Kinder- und Jugendmedizin | St. Gallen | Saint Gallen |
Lead Sponsor | Collaborator |
---|---|
Bioforce AG |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | tolerability assessment by physicians | Within the observation period of 4 months a maximum of 3 colds can be treated with Echinaforce Junior tablets at the indicated dosage. At the exclusion visit the physicians rate the tolerability of Echinaforce Junior tablets as "very good", "good", "moderate" or "bad" | 4 months | |
Secondary | tolerability assessment by parents/child | The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months | 4 months | |
Secondary | tolerability assessment by parents/child | The tolerability of Echinaforce Junior is assessed after every acute treatment period of 10 days and after the observation period of 4 months | 10 days | |
Secondary | Assessment of efficacy by parents/child | The acute efficacy of Echinaforce Junior is rated by the parents after every acute treatment period of 10 days as well as after the observation period of 4 months | 4 months | |
Secondary | Assessment of Cold Symptoms during Acute Treatment | During acute colds parents complete a symptom diary and assess cold-related symptoms (runny and congested nose, sneezing, headache, joint pain, sore-throat, fever, cough, shivering, sleep quality, additional care) in the child | 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Withdrawn |
NCT04842331 -
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
|
Phase 2/Phase 3 | |
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT00382408 -
A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001
|
Phase 3 | |
Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT05907564 -
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
|
N/A | |
Not yet recruiting |
NCT05534685 -
Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia
|
N/A | |
Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT05056766 -
How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
|
||
Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05565872 -
Effects of Supervision During a Community-based Exercise Intervention (Urban Training) in Patients With COPD
|
N/A | |
Not yet recruiting |
NCT05592431 -
Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Neonates
|
N/A | |
Completed |
NCT03401463 -
Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar
|
N/A | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Active, not recruiting |
NCT01055990 -
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
|
Phase 2 | |
Completed |
NCT00743990 -
Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough
|
N/A | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |